Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
- PMID: 25490934
- PMCID: PMC4270159
- DOI: 10.7554/eLife.04037
Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
Abstract
The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered Report describes the proposed replication plan of key experiments from "Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors" by Wilson and colleagues, published in Nature in 2012 (Wilson et al., 2012). The experiments that will be replicated are those reported in Figure 2B and C. In these experiments, Wilson and colleagues show that sensitivity to receptor tyrosine kinase (RTK) inhibitors can be bypassed by various ligands through reactivation of downstream signaling pathways (Figure 2A; Wilson et al., 2012), and that blocking the receptors for these bypassing ligands abrogates their ability to block sensitivity to the original RTK inhibitor (Figure 2C; Wilson et al., 2012). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.
Keywords: Reproducibility Project: Cancer Biology; biochemistry; human; methodology; receptor tyrosine kinase inhibitors; signaling pathway reactivation.
Conflict of interest statement
EG: The Monoclonal Antibody Core Facility is a Science Exchange associated laboratory.
RP:CB: EI, FT and JL are employed and holds shares in Science Exchange Inc.
The other authors declare that no competing interests exist.
Comment on
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249. Nature. 2012. PMID: 22763448 Free PMC article.
Similar articles
-
Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.Elife. 2014 Dec 10;3:e04034. doi: 10.7554/eLife.04034. Elife. 2014. PMID: 25490933 Free PMC article.
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249. Nature. 2012. PMID: 22763448 Free PMC article.
-
Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Elife. 2016 Mar 21;5:e11414. doi: 10.7554/eLife.11414. Elife. 2016. PMID: 26999821 Free PMC article.
-
[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31. Ann Pathol. 2013. PMID: 24331719 Review. French.
-
Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.Am Soc Clin Oncol Educ Book. 2013. doi: 10.14694/EdBook_AM.2013.33.e80. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714462 Review.
Cited by
-
Dual blockage of STAT3 and ERK1/2 eliminates radioresistant GBM cells.Redox Biol. 2019 Jun;24:101189. doi: 10.1016/j.redox.2019.101189. Epub 2019 Apr 9. Redox Biol. 2019. PMID: 30986607 Free PMC article.
-
Challenges for assessing replicability in preclinical cancer biology.Elife. 2021 Dec 7;10:e67995. doi: 10.7554/eLife.67995. Elife. 2021. PMID: 34874008 Free PMC article.
-
Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology.Elife. 2021 Dec 7;10:e73430. doi: 10.7554/eLife.73430. Elife. 2021. PMID: 34874009 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
